iSonea expands board expertise with new director appointments – Proactive Investors Australia


Proactive Investors Australia

iSonea expands board expertise with new director appointments
Proactive Investors Australia
iSonea recently reached an important milestone with the start of its first large US post-market study of its WheezoMeter™ monitoring device in paediatric patients with a range of asthma symptom severity. The study will include patients who are too
iSonea debuts asthma app platformFierceMobileHealthcare (press release)

all 2 news articles »

View full post on asthma – Google News

iSonea reaches milestone with launch of U.S. paediatric asthma study – Proactive Investors USA & Canada


mobihealthnews

iSonea reaches milestone with launch of U.S. paediatric asthma study
Proactive Investors USA & Canada
iSonea (ASX: ISN, OTCQX: ISOAY) has begun its first large US post-market study of its WheezoMeter™ monitoring device in paediatric patients with a range of asthma symptom severity. The study will include patients who are too young to be tested with
iSonea Announces Initiation of Pediatric Asthma StudyMarketWatch (press release)
iSonea begins recruiting for pediatric asthma trialmobihealthnews
iSonea to Build Mobile Asthma Management Apps on Qualcomm's PlatformHighlight HEALTH 2.0

all 15 news articles »

View full post on asthma – Google News

iSonea begins recruiting for pediatric asthma trial – mobihealthnews


Proactive Investors Australia

iSonea begins recruiting for pediatric asthma trial
mobihealthnews
The Asthma Sense iPhone app pictured is not yet available in the AppStore. iSonea, makers of the WheezoMeter, has begun recruiting for a post-market study of its asthma monitoring device for children under the age of 12 years old.
iSonea Announces Initiation of Pediatric Asthma StudyMarketWatch (press release)
iSonea reaches milestone with launch of U.S. paediatric asthma studyProactive Investors Australia
iSonea to Build Mobile Asthma Management Apps on Qualcomm's PlatformHighlight HEALTH 2.0

all 11 news articles »

View full post on asthma – Google News

iSonea to Develop New Asthma Mobile Health Technology Based on Qualcomm 2net Hub

The medical technology company iSonea Ltd. (ASX: ISN; OTCQX: ISOAY), announced that it will design and market a home and mobile asthma monitoring platform with global telecommunications corporation Qualcomm Life Inc.,™ a wholly owned subsidiary of Qualcomm Incorporated (NASDAQ: QCOM). The new technology will combine iSonea’s proprietary Acoustic Respiratory Monitoring (ARM)™ devices and mobile health asthma management systems with Qualcomm’s 2net™ platform.

“Asthma is a widespread and growing condition that affects 300 million people worldwide and represents a major healthcare cost burden”

The integration will automatically and securely link patient asthma symptom and trend monitoring data to a cloud-based portal for physicians and caregivers, to improve asthma management and outcomes.

The effort leverages Qualcomm Life’s 2net Hub, a plug-and-play connectivity gateway to the cloud-based 2net platform data server, to collect and transmit patient health data from iSonea’s monitoring devices. The technology will ultimately allow physicians to securely access patient monitoring data, review treatment progress and medication adherence and adjust patient action plans accordingly. Family and caregivers will be able to view trends for reassurance about patient care.

“Asthma is a widespread and growing condition that affects 300 million people worldwide and represents a major healthcare cost burden,” said Michael J. Thomas, Chief Executive Officer of iSonea Limited. “With our smartphone platform and Qualcomm’s end-to-end wireless systems expertise, we will provide asthma patients with the ability to monitor and report breathing distress symptoms triggered by environmental factors, as well as their response to treatment. Better daily monitoring can lead to improved medication compliance, lower healthcare costs and improved chronic management of asthma. For patients or family members, better monitoring also means more peace of mind.”

Qualcomm’s wireless solutions will enable iSonea’s ARM-based mobile asthma management products, in a cost-effective and scalable manner, to:

Connect and securely transmit data to a cloud-based site for analysis;
Provide protected data access to physicians, caregivers, family and patients; and
Give consumers an easy-to-use dashboard to view and manage their asthma trends.

iSonea’s Senior Vice President of Operations Steve Tunnell added, “Qualcomm understands the need for wireless solutions that will link with self-monitoring devices to allow data sharing in the new ‘smart home.’ Integrating our acoustic respiratory monitoring sensors and software with the Qualcomm 2net Hub will help people share their asthma management data with physicians, family and caregivers, alerting them to critical changes.”

About iSonea Limited

iSonea Limited (ASX:ISN; OTCQX:ISOAY) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea’s proprietary Acoustic Respiratory Monitoring™ (ARM) technology with its AsthmaSense™ mobile applications, iSonea is turning smartphones into medical devices–enabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea’s ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE. For more information, please visit www.iSoneaMed.com.

About Qualcomm

Qualcomm (NASDAQ: QCOM) is an American global telecommunications company which designs, manufactures and markets digital wireless telecommunications products and services based on its code division multiple access (CDMA) technology and other technologies. It is headquartered in San Diego, California, USA.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on iSonea’s current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,“ “guidance” and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Contacts

iSonea Limited
Mr. Michael Thomas, +1 410-777-5251
Chief Executive Officer
mthomas@iSoneaMed.com
www.iSoneaMed.com
or
Schwartz MSL Boston
Helen Shik or Jennifer Netzband, +1 781-684-0770
iSonea@schwartzmsl.com
www.schwartzmsl.com

iSonea Showcases Asthma Monitoring Technology at HIMSS – SunHerald.com


Proactive Investors Australia

iSonea Showcases Asthma Monitoring Technology at HIMSS
SunHerald.com
SEVERNA PARK, Md. & LAS VEGAS — Medical technology company iSonea Ltd. (ASX: ISN; OTCQX: ISOAY), will be showcasing its asthma monitoring technology at the 2012 Annual HIMSS Conference & Exhibition being held at the Venetian-Sands Expo Convention
iSonea's new asthma monitoring technology to feature at prestigious Las Vegas expoProactive Investors USA & Canada

all 11 news articles »

View full post on asthma – Google News

iSonea Showcases Asthma Monitoring Technology at HIMSS

Medical technology company iSonea Ltd. (ASX: ISN; OTCQX: ISOAY), will be showcasing its asthma monitoring technology at the 2012 Annual HIMSS Conference & Exhibition being held at the Venetian-Sands Expo Convention Center in Las Vegas from February 21 – 23. Visit iSonea in the Qualcomm Life Pavilion Booth #13234.

iSonea will be showing its WheezoMeter? device and previewing the first version of its AsthmaSense? mobile health application — both designed to help asthma patients, their families, caregivers and physicians to monitor asthma symptoms on an ongoing basis.

iSonea’s WheezoMeter? device is based on the company’s Acoustic Respiratory Monitoring? (ARM) technology platform, which uses acoustic sensors and novel signal processing software to establish the presence, frequency and severity of wheeze. In essence a ‘thermometer’ for wheeze, the portable device records and analyzes sounds caused by inflammation or narrowing of the airways, to quantify the rate of wheezing, a hallmark symptom of asthma. The technology correlates to traditional lung function tests, but is more patient friendly, enabling frequent monitoring in real-life settings. The device requires no physical exertion and can be used to interpret respiratory symptoms by all asthma patients, including young children or the elderly.
The soon-to-be-introduced AsthmaSense? smartphone applications from iSonea will enable anyone, anywhere, at any time to better manage their asthma. Among the first version’s features, AsthmaSense will have a tracking system to monitor trends of symptoms, triggers, test results (peak flow measurements and WheezeRate?) and medication usage/ adherence.

iSonea recently announced a technology development initiative to design and market a home and mobile asthma monitoring platform. For more information on this collaborative platform, and for updates on HIMSS activities, go to http://www.iSoneaMed.com and follow SoundAsthma on Twitter (@soundasthma).

About iSonea Limited

iSonea Limited (ASX:ISN; OTCQX:ISOAY) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea’s proprietary Acoustic Respiratory Monitoring? (ARM) technology with its AsthmaSense? mobile applications, iSonea is turning smart phones into medical devices–enabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea’s ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE. For more information, please visit www.iSoneaMed.com.

iSonea Limited
Mr. Michael Thomas, +1 410-777-5251
Chief Executive Officer
mthomas@iSoneaMed.com
www.iSoneaMed.com
or
Schwartz MSL Boston
Helen Shik or Jennifer Netzband, +1 781-684-0770
iSonea@schwartzmsl.com
www.schwartzmsl.com

iSonea rapidly approaches commercialisation, targets US$16 billion asthma market – Proactive Investors USA & Canada


mobihealthnews

iSonea rapidly approaches commercialisation, targets US$16 billion asthma market
Proactive Investors USA & Canada
iSonea (ASX: ISN) is preparing to roll out a number of its asthma products over the next 24 months after entering its first formal partnership with telecommunications company Qualcomm Life for the development of a mobile asthma monitoring platform.
iSonea to Develop New Asthma Mobile Health Technology Based on Qualcomm 2net HubEON: Enhanced Online News (press release)
Qualcomm Life, iSonea to offer mobile asthma monitormobihealthnews
iSonea gains partner to develop new mobile asthma monitoring systemProactive Investors UK

all 16 news articles »

View full post on asthma – Google News